It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on Wednesday. Several doses of Novo's GLP-1 therapies such as Wegovy and diabetes drug Ozempic,

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,

The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable Difficulties for Compounding Lists."

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as "available" on the U.S. Food and Drug Administration's drug shortage list. The change in status comes nearly six months after Novo Nordisk,

Novo has been racing to boost supplies of its drugs for obesity and diabetes after initially underestimating demand.